Welcome to our dedicated page for Pfizer SEC filings (Ticker: PFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pfizer Inc. filings document the financial, governance, capital-structure, and material-event disclosures of a global biopharmaceutical company. The company's 8-K reports include quarterly operating results, financial guidance updates, Regulation FD disclosures, clinical or regulatory disclosure categories, material agreements, and other corporate events tied to its medicines, vaccines, pipeline, and commercial organization.
Pfizer's proxy and annual-meeting filings cover board elections, auditor ratification, executive compensation, shareholder voting results, and equity-plan governance. Its capital markets filings and 8-K exhibits also disclose common stock, NYSE-listed notes, shelf registration activity, public debt offerings, note maturities, and related capital-structure terms.
Pfizer Inc. Executive Vice President Michael McDermott reported several equity-related transactions involving Pfizer common stock and stock appreciation rights. On February 25, 2026, he exercised 37,925 stock appreciation rights, which were settled in Pfizer common stock as part of an earn-out of these awards, including dividend equivalents. This exercise generated 37,925 common shares at a reference price of $33.82 per share, increasing his direct common stock holdings.
In connection with this earn-out and related restricted stock unit vesting, Pfizer withheld shares to cover tax obligations and exercise price. These withholding dispositions of common stock totaled 3,503 shares on February 26, 2026 at $27.10, plus 679 shares and 36,044 shares on February 25, 2026 at prices of $27.09 and $26.92 per share, respectively. After these transactions, McDermott directly held 74,308 Pfizer common shares, with the derivative stock appreciation rights position reported as fully settled.
Pfizer Inc. President of R&D Christoffel Boshoff reported equity award activity involving Pfizer common stock. On February 25, 2026, he acquired 13,383 shares at $0.0000 per share as the earn-out of performance share awards, including dividend equivalents, increasing his direct holdings to 168,212 shares.
On the same date, 6,833 shares were disposed of at $27.09 per share to cover tax obligations related to this earn-out, a tax-withholding disposition rather than an open-market sale, leaving 161,379 shares held directly. He also indirectly holds 709 shares through a Rule 16b-3 plan.
Pfizer Inc. provides a comprehensive annual overview of its global biopharmaceutical business, strategy, risks and intellectual property. The company operates mainly through its Biopharma segment, supported by contract manufacturing (PC1), while winding down Pfizer Ignite.
Pfizer reports $25.5 billion of 2025 revenue from operations outside the U.S., representing 41% of total revenues, with China and Japan highlighted as key markets. It details major products and patent expirations through 2041, emphasizes oncology, vaccines, cardiometabolic and immunology R&D, and outlines 2026 priorities: maximizing key transactions, delivering critical R&D milestones, investing for post‑2028 growth, and scaling AI across the business.
Pfizer Inc. President, R&D Christoffel Boshoff had 816 shares of common stock withheld on February 23, 2026 to cover tax obligations upon the vesting of restricted stock units, at a price of $27.06 per share. After this tax-withholding disposition, he directly holds 154,829 shares and indirectly holds 709 shares through a Rule 16b-3 plan.
Pfizer Inc. senior vice president and controller Jennifer B. Damico reported a tax-related share disposition. On the vesting of restricted stock units, 419 shares of common stock were withheld at $27.06 per share to satisfy tax obligations, leaving her with 12,186 directly held shares.
Pfizer Inc. Chairman and CEO Albert Bourla reported an acquisition of derivative securities linked to Pfizer common stock. On 02/12/2026, he received 2,883 Phantom Stock Units SSP at $27.47 per unit under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
Each unit represents one phantom share of common stock and is settled in cash after his separation from service. Following this grant, Bourla beneficially owned 757,286 derivative units on a direct basis, providing additional deferred, cash-settled exposure to Pfizer’s share value rather than immediate stock ownership.
Pfizer Inc. Chairman and CEO Albert Bourla reported an acquisition of derivative securities linked to Pfizer common stock. On 02/12/2026, he received 2,883 Phantom Stock Units SSP at $27.47 per unit under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
Each unit represents one phantom share of common stock and is settled in cash after his separation from service. Following this grant, Bourla beneficially owned 757,286 derivative units on a direct basis, providing additional deferred, cash-settled exposure to Pfizer’s share value rather than immediate stock ownership.
Pfizer Inc. reports beneficial ownership of 22,032,040 shares of Allogene Therapeutics, Inc. common stock, representing 9.0% of the class. This percentage is based on 224,730,144 shares outstanding as of November 4, 2025, as reported in Allogene’s Form 10-Q. The lower ownership percentage in this amendment results solely from Allogene issuing more shares, not from Pfizer selling or buying stock. Pfizer and its listed executives report no transactions in Allogene shares during the prior 60 days.
Pfizer Inc. reports beneficial ownership of 22,032,040 shares of Allogene Therapeutics, Inc. common stock, representing 9.0% of the class. This percentage is based on 224,730,144 shares outstanding as of November 4, 2025, as reported in Allogene’s Form 10-Q. The lower ownership percentage in this amendment results solely from Allogene issuing more shares, not from Pfizer selling or buying stock. Pfizer and its listed executives report no transactions in Allogene shares during the prior 60 days.
Pfizer Inc filed a Form 13F reporting its institutional holdings. The report lists 21 securities entries with a total reported market value of $236,464,562 as shown on the Form 13F summary page. The filing was signed by Madelyn D. Purcell, Assistant General Counsel on 02-10-2026.
Pfizer Inc. filed a current report to make investors aware that it has released its financial results for the fourth quarter of 2025. The company did this by issuing a press release on February 3, 2026, which is attached to the report as Exhibit 99.
The press release is formally provided for information purposes and is not treated as being legally “filed” under certain securities law provisions. The filing also includes an Inline XBRL cover page data file as Exhibit 104.
Pfizer Inc. filed a current report to make investors aware that it has released its financial results for the fourth quarter of 2025. The company did this by issuing a press release on February 3, 2026, which is attached to the report as Exhibit 99.
The press release is formally provided for information purposes and is not treated as being legally “filed” under certain securities law provisions. The filing also includes an Inline XBRL cover page data file as Exhibit 104.
Pfizer Inc. executive Christoffel Boshoff reported a tax‑related share withholding tied to equity compensation. On January 30, 2026, 12,887 shares of Pfizer common stock were withheld at $26.44 per share to satisfy tax obligations upon vesting of restricted stock units, rather than being an open‑market sale. After this transaction, Boshoff beneficially owned 155,645 shares directly and 698 shares indirectly through a Rule 16b‑3 plan.